Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b

Archives of Dermatology

Volumn 132, Issue 3, 1996, Pages 285-290

  Costa Da Cunha, Claudia S ^a   Lebbé, Céleste ^a   Rybojad, Michel ^a   Agbalika, Félix ^a   Ferchal, Françoise ^a   Rabian, Claire ^a   Vignon Pennamen, Marie D ^a   Calvo, Fabien ^a   Morel, Patrice ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; KAPOSI SARCOMA; LIVER TOXICITY; MALE; NEUTROPENIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CD4-CD8 RATIO; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2A; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SARCOMA, KAPOSI; TREATMENT OUTCOME;

EID: 0004784404     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.132.3.285     Document Type: Article

References (30)

1. Chor PJ, Santa Cruz DJ. Kaposi's sarcoma: a clinicopathologic review and differential diagnosis J Cutan Pathol. 1992;19:6-20
2. Holden CA Histogenesis of Kaposi's sarcoma and angiosarcoma of the face and the scalp. J Invest Dermatol. 1989;93:119S-124S.
3. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;26:1865-1869.
4. Ambroziak J, Blackbourn D, Herndier B, et al. Herpes like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science 1995;268.582-583.
5. Su I, Hsu Y, Chang Y, Wang IW. Herpes virus-like sequence in Kaposi's sarcoma for AIDS and non AIDS patients in Taiwan Lancet 1995;345 722-723.
6. Huang Y, Li J, Kaplan M, et al. Human herpes virus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet 1995;345.759-761.
7. Dupin N, Grandadam M, Calvez V, et al. Herpes virus-like DNA sequences in patients with mediterranean KS Lancet 1995;345:761-762.
8. Lebbé C, de Crémoux P, Rybojad M, Costa da Cunha C, Morel P, Calvo F. Kaposi's sarcoma and new herpes virus Lancet. 1995:345-1180.
9. Boshoff G, Whitby D, Hatziioannou T, et al. Kaposi's sarcoma associated herpes virus in HIV negative Kaposi's sarcoma Lancet. 1995,345:1043-1044.
10. Moore P, Chang Y. Detection of herpes virus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med. 1995; 332:1181-1185.
11. Schalling M, Ekman M, Kaaya E, Linde A, Biberfeld P. A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma. Nature Med. 1995;1:707-708.
12. Roth WK, Brandstetter H, Sturzl M. Cellular and molecular features of HIV-associated Kaposi's sarcoma. AIDS. 1992;6:895-913.
13. Lilebaun RC, Ratner L Systemic treatment of Kaposi's sarcoma: current status and future directions. AIDS. 1994;8:141-151.
14. Mitsuyasu RT. Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma Br J Haematol. 1991;79(suppl 1):S69-S73.
15. Rybojad M, Borradory L, Verola O, Zeller I, Puissant A, Morel P Non-AIDS associated Kaposi's sarcoma (classical and endemic African types): treatment with low doses of recombinant interferon-alpha J Invest Dermatol. 1990;95. 176S-179S.
16. Kriegel RL, Laubstein LJ, Muggia FM Kaposi's sarcoma: a new staging classification. Cancer Treat Rep. 1983;67:531-534.
17. Saven A, Piro LD. Treatment of hairy cell leukemia: review. Blood. 1992;5: 1111-1120.
18. Reiter Z, Ozés ON, Blatt LM, Sturzl M, Taylor MW. A possible role for interferon alpha and activated natural killer cells in remission of AIDS-related Kaposi's sarcoma: in vitro studies. J Acquir Immune Defic Syndr. 1992;5:469-476.
19. Krown SE. AIDS-associated Kaposi's sarcoma: pathogenesis, clinical course and treatment AIDS. 1988,2:71-80.
20. Real FX, Krown SE, Oettgen HF. Kaposi's sarcoma and the acquired immundeficiency syndrome treatment with high and low doses of recombinant leucocyte A interferon. J Clin Oncol. 1986;4.544-551.
21. Krown SE, Gold JWM, Niedzwiecki D, et al. Interferon alpha with zidovudine: safety, tolerance, and clinical virologic effects with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) Ann Intern Med 1990; 112:812-821.
22. Thiele B, Schuff-Werner P, Rahlf G, Mahrle G, Ippen H. 'Klassische Form' des Kaposi-Sarkoms. Immunologie und Interferontherapie Hautarzt. 1984;35:349-353.
23. Bourlond A, Dubois D, de Sélys R. Sarcome de Kaposi: traitement par facteur de transfert et interferon-alpha-2. Dermatologica. 1987;174:199-205.
24. Contu L, Sulis E, Cerimele D, La Nasa G, Pintus A, Pitzus F The role of alpha-interferon in the therapy of Kaposi's sarcoma (AIDS and classic forms) and of cutaneous T cell lymphoma In: Bernasconi C, ed New Trends in the Therapy of Leukemia and Lymphoma. Pavia, Italy: Edizioni Medico Scientifica; 1987:89-100
25. Dettke T, Melgel W, Kolb H, Kern P. Klassische Form des Kaposi-Sarkoms-Immunologie und Therapie Akt Dermatol. 1988;14:113-116.
26. Killeen RB, DeWilton Marsh R. Alpha-interferon for Kaposi's sarcoma in HIV-negative, non-homosexual men. Lancet. 1991;337:309-310
27. Tur E, Brenner S, Michalevitcz R. Low-dose recombinant interferon alfa treatment for classic Kaposi's sarcoma. Arch Dermatol. 1993;129:1297-1300.
28. Safai B, Mike V, Giraldo G, Beth E, Good RA. Association of Kaposi's sarcoma with second primary malignancies. Cancer 1980;146:115-122.
29. Tratner A, Reizis Z, David M, et al. The therapeutic effect of intralesional interferon in classical Kaposi's sarcoma. Br J Dermatol. 1993;129:590-593.
30. Mirailles ES, Pérez B, Núnez M. Low-dose recombinant interferon alpha treatment for classic Kaposi's sarcoma. Arch Dermatol 1994;130:799-800.